Genetic polymorphisms result in interindividual variation in DNA repair capacity and may, in part, account for susceptibility of a cell to genotoxic agents and to malignancy. Polymorphisms in XPD, a member of the nucleotide excision repair pathway, have been associated with development of treatment-related acute myeloid leukemia (AML) and with poor outcome of AML in elderly patients. We hypothesized that XPD Lys751Gln polymorphism may play a role in causation of AML in children and, as shown in adults, may affect the outcome of childhood AML therapy. Genotyping of 456 children treated for de novo AML was performed at XPD exon 23. Genotype frequencies in patients were compared with healthy control subject frequencies, and patient outcomes were analyzed according to genotype. Gene frequencies in AML patients and healthy controls were similar. There were no significant differences in overall survival (P ‫؍‬ .82), eventfree survival (P ‫؍‬ .78), treatment-related mortality (P ‫؍‬ .43 
Introduction
DNA is continuously damaged by endogenous and exogenous mutagens. Repair of DNA damage is a complex process carried out by an array of DNA repair pathways, including nucleotide excision and base excision repair pathways. The nucleotide excision repair (NER) pathway eliminates the widest variety of damage to the human genome, including UV-induced photoproducts, bulky monoadducts, cross-links, and oxidative damage. 1 Hereditary genetic defects in DNA repair lead to increased risk of cancer. Individuals with xeroderma pigmentosum (XP), a rare autosomal recessive disease resulting from a defect in NER of UV-damaged DNA, have a 1000-fold increased risk of skin cancer. 2 Cell-fusion analyses have identified 7 genetic complementation groups (XPA to XPG) that encode for proteins participating in different steps of the NER pathway. 3, 4 Xeroderma pigmentosum complementation group D (XPD) is a major participant in NER pathway and is also involved in transcription initiation, control of cell cycle, and apoptosis. 5 XPD functions as an evolutionarily conserved ATP-dependent helicase within the multisubunit transcription repair factor complex, TFIIH. [6] [7] [8] TFIIH has 2 distinct roles, first in basal transcription carried out by RNA polymerase II and second in NER of DNA damage. It appears that XPD protein needs to be present to maintain the stability of the TFIIH complex. XPD possesses both single-strand DNA-dependent ATPase and 5Ј-3Ј DNA helicase activities and is thought to participate in DNA unwinding during NER and transcription. 9, 10 Mutations in the XPD gene can completely prevent DNA opening and dual incision, steps that lead to the repair of DNA adducts. 11 Genetic polymorphisms result in interindividual variation in DNA repair capacity and may, in part, account for differences in susceptibility of a cell to genotoxic agents and to malignancy. 12, 13 Several single nucleotide polymorphisms, including an adenine (A) to cytosine (C) (A 3 C) transition, which leads to Lys751Gln in exon 23 of the XPD gene, have been shown to be associated with elevated frequency of chromosomal aberrations and a variety of environmentally induced cancers in adults. [14] [15] [16] [17] There is also evidence that dysregulation of DNA repair proteins and NER pathways may be involved in pathogenesis and prognosis of some myeloid leukemia.
Recent data from elderly acute myeloid leukemia (AML) patients treated on MRC11 trial showed reduced event-free survival (EFS) and overall survival (OS) along with increased risk of developing treatment-related leukemia in XPD751 glutamine homozygotes (CC), suggesting that the glutamine variant confers greater protection against chemotherapy-induced leukemic blastcell death, leading to earlier disease relapse and ultimately shorter overall survival. 18 In this study we show that, in contrast to the adult data, XPD751 does not influence outcome of therapy in children with AML.
Patients, materials, and methods

Patients
The study population included 456 children with de novo AML treated on Children's Cancer Group (CCG) therapeutic studies CCG-2941 (n ϭ 37) and CCG-2961 (n ϭ 419) between 1995 and 2002. Clinical data, including age, sex, white blood cell (WBC) count at diagnosis, race, presence of chloroma, presence of central nervous system (CNS) disease, and immunophenotype were collected prospectively (Table 1) . Cases were classified on the basis of criteria established and revised by the French-American-British (FAB) Cooperative Study Group by central pathology review. All FAB categories except acute promyelocytic leukemia (APL-AML M3) were eligible for enrollment and were treated with the same chemotherapy regimens.
We randomly selected 578 healthy blood donors to determine control genotype frequencies: 432 were white and 146 were black controls.
Chemotherapy treatment regimen
CCG-2961 study was a randomized phase 3 trial of intensively timed induction, consolidation, and intensification therapy for pediatric patients with previously untreated AML or myelodysplastic syndrome (MDS). 19 The study was conducted between August 1996 and December 2002. CCG-2941 was a feasibility pilot of the same chemotherapy regimen that preceded the randomized study. Induction included 5 drugs: idarubicin, etoposide, dexamethasone, cytarabine, and 6-thioguanine (IDA DCTER) given on days 0 to 3 followed by 5 drugs (daunorubicin, etoposide, dexamethasone, Ara-C, and 6-thioguanine) (DCTER) given on days 10 to 13. 20 Upon recovery of white blood cell and platelet counts, patients were 
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Normal 28 (23) 27 (23) 11 (31 randomly assigned to consolidation therapy consisting of the same sequence of drugs or to fludarabine/cytarabine/idarubicin. Intrathecal cytarabine was used for CNS prophylaxis. Patients with matched-related donors were assigned to allogeneic marrow transplant intensification. Pretransplant cytoreduction was busulfan and cyclophosphamide. Patients without a related donor received high-dose cytarabine/L-asparaginase (Capizzi II) and additional intrathecal cytarabine. After recovery from chemotherapy, patients were randomized again to either receive interleukin-2 or standard follow-up care. Patients who received transplants were not eligible for randomization to interleukin-2.
XPD genotyping
DNA extracted from diagnostic marrow samples using standard methods was normalized to 10 ng/L. Genotyping was performed using a fluorescence-based allelic discrimination assay (TaqMan; Applied Biosystems, Foster City, CA). Gene-specific polymerase chain reaction (PCR) primers and fluorogenic probes for allelic discrimination are described in Table 2 . PCR cycling reactions were performed in 96-well microtiter plates in a GeneAmp PCR System 9600 (Perkin-Elmer). For each 25-L reaction, 10 ng DNA template was added to the reaction mixture containing wild-type VIC and variant FAM probe, PCR mastermix (Applied Biosystems), and forward and reverse primers (final concentration 0.3 M). Thermocycling was performed with an initial 50°C incubation for 2 minutes followed by a 10-minute incubation at 95°C. A 2-step cycling reaction was performed for 40 cycles with denaturation at 95°C for 15 seconds, and annealing and extension at 62°C for 1 minute. Results were analyzed by the automated TaqMan allelic discrimination assay using sequence detection system 2.1 software (ABI TaqMan 7700, Applied Biosystems).
DNA from healthy controls was extracted using standard techniques and genotyped as described for cases. Genotyping results were duplicated in 10% of samples; concordance between repeats was 100%. Furthermore, 10% of the samples also were genotyped using direct sequencing; concordance with TaqMan genotyping was 100%.
Statistical analysis
Data were analyzed from CCG-2941 and CCG-2961 through April 2005 for both studies. The significance of observed differences in proportions was tested using the Chi-square test and Fisher exact test when data were sparse. The Mann-Whitney test was used to determine the significance between differences in medians. 21 The Kaplan-Meier method was used to calculate estimates of OS, EFS, and disease-free survival (DFS). 22 Estimates are reported with their Greenwood standard errors. 23 Differences in these estimates were tested for significance using the log-rank statistic. 24 OS is defined as time from study entry to death from any cause. EFS is defined as time from study entry to failure at the end of 2 courses, relapse, or death from any cause. DFS is defined as time from the end of one course of therapy to failure at the end of 2 courses, relapse, or death from any cause. Cumulative incidence estimates were used to determine relapse rate (RR) and treatment-related mortality (TRM). RR is defined as time from the end of one course of therapy to failure at the end of 2 courses, relapse, or death from progressive disease where deaths from nonprogressive disease were competing events. TRM is defined as time from study entry to death from nonprogressive disease where failures at the end of 2 courses, relapses and deaths from progressive disease were competing events. Differences between RR or TRM estimates were tested for significance using Gray test. 25 Children lost to follow-up were censored at their date of last known contact or at a cutoff 6 months prior to April 2005. Cox regression was used for multivariate models that looked at differences between groups adjusting for study assignment, age, sex, race, and WBC count.
Results
Genotype frequencies
Allele and genotype frequencies for cases and controls are shown in Table 3 . XPD genotype frequencies for black and white controls were significantly different (P Ͻ .001). Genotype frequencies did not differ by sex (data not shown). Comparison of genotype frequencies was therefore performed separately for white cases versus white controls and black cases versus black controls. Genotype frequencies were similar in white cases and controls (Table 3 ; P ϭ .125) and black patients and black controls (P ϭ .239). The distribution of XPD genotypes was consistent with the Hardy-Weinberg equilibrium. Stratification of cases by age at diagnosis (0-2 y vs Ͼ 2-10 y vs Ͼ 10 y), WBC count at diagnosis (Ͻ 50 000 vs Ն 50 000), AML subtype, or cytogenetics revealed no difference in genotype frequencies. There were more XPD 751AC patients compared to AA in hyperdiploid cases; however, this difference should be interpreted cautiously due to the very small total number of patients with hyperdiploidy.
XPD genotype and outcome
There were no significant differences in OS from study entry between patients with XPD 751AA versus 751AC versus 751CC genotypes (53% Ϯ 8% vs 50% Ϯ 8% vs 45% Ϯ 13% respectively at 5 years; log-rank P ϭ .82; Figure 1 ). In addition, induction of remission did not vary by genotype (Table 1) . When OS from end of one course of therapy for patients in remission was compared between different genotypes, there was no statistical difference between polymorphism subgroups; 57% Ϯ 8% in XPD751AA versus 58% Ϯ 8% in AC versus 52% Ϯ 15% in CC patients at 5 years (log-rank P ϭ .96).
Analysis of EFS from study entry in different genotypes also showed similar estimates: 41% Ϯ 7% in XPD751AA versus 38% Ϯ 7% in AC versus 41% Ϯ 13% in CC patients at 5 years (log-rank P ϭ .78) (Figure 2) . DFS from the end of one course of therapy for patients in remission also was similar among the 3 Cases versus controls: white, P ϭ .125; black, P ϭ .239. *P for comparisons between white patients and white controls. †P for comparisons between black patients and black controls. BLOOD
There was no difference in TRM from study entry between different genotypes (18% Ϯ 6% in AA vs 16% Ϯ 5% in AC vs 12% Ϯ 8% in CC patients at 5 years; P ϭ .43) (Figure 3) . RRs from the end of one course of therapy for patients in remission were also similar: 40% Ϯ 8% in XPD 751AA versus 42% Ϯ 8% in 751AC versus 39% Ϯ 14% in 751CC patients at 5 years (P ϭ .92) (Figure 4) . Thus, XPD genotype was not significantly associated with either resistant disease or treatment-related toxicity.
Discussion
Pharmacogenetic polymorphism and variations in response to damage induced by chemotherapy are being intensively investigated as causes of differential susceptibility to leukemogenesis and differential response to therapy. [26] [27] [28] When investigating the clinical consequences of human polymorphism, it is important to target polymorphisms that likely change protein function and occur at significant frequencies in the population. Spitz et al 29 studied the functional consequences of the XPD Lys751Gln polymorphism among lung cancer patients and healthy controls. They reported that the variant Gln751Gln genotype was consistently associated with the suboptimal DNA repair capacity (DRC). This was determined by assessing the ability of host cells to remove DNA adducts induced by benzo(a)pyrene, a major constituent of tobacco smoke. This association was statistically significant among the lung cancer cases but not among the healthy controls, indicating a role for XPD in tobacco-related cancers. These data are controversial, however, and others such as Duell et al and Moeller et al reported no significant relationship between XPD Lys751Gln polymorphism and DNA repair proficiency. 30, 31 These conflicting results have led to suggestions that functionality of the codon 751 polymorphism may be exposure-and pathway-specific, affecting both DNA repair and cell death. 32 Consistent with a role for XPD in cell death, P53-mediated apoptosis is attenuated in XPD mutated fibroblasts. 33, 34 Furthermore, P53 interacts directly with the carboxy terminus of XPD, which includes the polymorphic codon 751 residue. 32 A previous report of adult subjects showed that XPD751 genotype influenced susceptibility to therapy-related leukemia, but not de novo AML. 18 In agreement with this, in this pediatric study we found no influence of XPD751 genotype on susceptibility to de novo AML in children. It should be noted that the present pediatric study focused on de novo and not therapy-related AML.
There is evidence that DNA repair (NER) protects against mutagenicity and toxicity by removing deleterious DNA lesions from the genome, including those induced by chemotherapy. [35] [36] [37] [38] Because increased DNA repair plays an important role in resistance to platinum-based compounds, Park et al evaluated the effect of XPD Lys751Gln polymorphism on outcome of 73 patients treated with 5-fluorouracil (5-FU)/oxaloplatin for metastatic colorectal cancer. Their results showed a significant association between response to 5-FU/oxaloplatin and the XPD Lys751Gln polymorphism. Patients with Lys/Lys genotype had the longest median survival, and those with Gln/Gln genotype were 6 to 12 times more likely to have progressive disease. 39 Allan et al evaluated the association of XPD Lys751Gln polymorphism with outcome following chemotherapy for AML in 341 elderly patients (Ͼ 60 years of age) entered into the United Kingdom Medical Research Council (MRC) AML 11 trial. 18 In this study XPD 751 glutamine homozygotes had significantly inferior DFS at 1 year compared with patients with other genotypes. The authors postulated 2 general mechanisms by which the XPD codon 751 variant may modulate myeloid-cell death in response to chemotherapy: either via a direct role for XPD in signaling cell death or indirectly via XPD repair of protoxic DNA lesions.
In contrast to the findings of Allan et al, 18 our study did not demonstrate any differences in outcome of AML therapy in children with different XPD 751 genotypes. It is possible that children with AML differ from adults in terms of the biology of their disease, for example, studies show that older adults have increased frequency of adverse cytogenetic features compared to children. 40, 41 Also, over time adult patients have more opportunity to accumulate additional genetic insults (secondary hits), with perhaps increased susceptibility to develop cancers that are more resistant to therapy. Outcomes for treatment of adult AML are commonly inferior to those reported in pediatric series. [42] [43] [44] [45] Also, association studies involving genetic polymorphisms need to be interpreted cautiously in the context of differences in study or population variables. For example, compared to children, older adults have poorer tolerance of combination chemotherapy regimens, leading to the use of less-intensive treatment protocols, as well as increased levels of primary drug resistance associated with overexpression of P-glycoprotein (P-gp). Adults in the study by Allan et al 18 received chemotherapy agents (daunomycin, cytosine arabinoside, thioguanine, etoposide) broadly similar to those received by the children in our study, but it is possible that the effect of XPD polymorphism is regimen specific. A subset of patients in the adult study received an alkylating agent (cyclophosphamide) in postremission therapy in contrast to our pediatric study, and half were randomized to interferon-␣, either of which may have influenced the results. Progress in AML therapy in children has largely been made by aggressive intensification of chemotherapy. It is also possible that intensification of chemotherapy in children can overcome a marginal modulating effect of XPD genotype. Additionally, this XPD variant may be of functional importance in children with AML when combined with other XPD variants or polymorphic alleles of other DNA repair genes. Mechanistic studies further defining the functionality of XPD polymorphisms will help clarify the importance of variants at this site.
